IP Library Granted Patent US 50,681
Granted Patent E1
US 50,681 · App. 17/958,932 · Granted Dec 2, 2025

Ionizable cationic lipid for RNA delivery

Inventors: Joseph E. Payne (San Diego, CA); Padmanabh Chivukula (San Diego, CA)
Assignee: Arcturus Therapeutics, Inc
C07C323/52A61K47/18A61K47/20C07C235/12C07C237/12C07C271/22C07C323/25C07C323/60C07C333/04C07J41/0055C11C3/04C12N15/111C12N15/113C12N15/1137C12N2310/14C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 50,681
App. No.
17/958,932
Granted
Dec 2, 2025
Kind
E1
Abstract

What is described is a compound of formula (1) wherein R 1 and R 2 are the same or different, each a linear or branched alkyl with 1-9 carbons, or an alkenyl or alkynyl with 2 to 11 carbon atoms; L 1 and L 2 are the same or different, each a linear alkyl having 5 to 18 carbon atoms, or form a heterocycle with N; X 1 is a bond, or is —CO—O— whereby L 2 -CO—O—R 2 is formed; X 2 is S or O; L 3 is a bond or a lower alkyl, or form a heterocycle with N; R 3 is a lower alkyl; and R 4 and R 5 are the same or different, each a lower alkyl; or a pharmaceutically acceptable salt thereof.

Claims (77)

1 . A compound of formula

wherein

R 1 and R 2 are the same or different, each a linear or branched alkyl consisting of 1 to 9 carbons, an alkenyl or alkynyl consisting of 2 to 11 carbons, or cholesteryl,

L 1 and L 2 are the same or different, each a linear alkylene or alkenylene consisting of 5 to 18 carbons,

X 1 is —CO—O— whereby -L 2 -CO—O—R 2 is formed,

X 2 is S or O,

X 3 is —CO—O— whereby -L 1 -CO—O—R 1 is formed,

L 3 is a bond,

R 3 is a linear or branched alkylene consisting of 1 to 6 carbons, and

R 4 and R 5 are the same or different, each hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons;

or a pharmaceutically acceptable salt thereof.

2 . The compound of claim 1 , wherein the X 2 is S.

3 . The compound of claim 1 , wherein the R 3 is ethylene.

4 . The compound of claim 1 , wherein the R 3 is n-propylene or isobutylene.

5 . The compound of claim 1 , wherein the R 4 and R 5 are separately methyl, ethyl, or isopropyl.

6 . The compound of claim 1 , wherein L 1 and L 2 are the same.

7 . The compound of claim 1 , wherein L 1 and L 2 differ.

8 . The compound of claim 1 , wherein L 1 or L 2 consists of a linear alkylene having seven carbons.

9 . The compound of claim 1 , wherein L 1 or L 2 consists of a linear alkylene having nine carbons.

10 . The compound of claim 1 , wherein R 1 and R 2 are the same.

11 . The compound of claim 1 , wherein R 1 and R 2 differ.

12 . The compound of claim 10 , wherein R 1 and R 2 each consists of an alkenyl.

13 . The compound of claim 10 , wherein R 1 and R 2 each consists of an alkyl.

14 . The compound of claim 12 , wherein the alkenyl consists of a single double bond.

15 . The compound of claim 10 , wherein R 1 or R 2 consists of nine carbons.

16 . The compound of claim 10 , wherein R 1 or R 2 consists of eleven carbons.

17 . The compound of claim 10 , wherein R 1 or R 2 consists of seven carbons.

18 . The compound of claim 1 , wherein L 3 is a bond, R 3 is ethylene, X 2 is S, and R 4 and R 5 are each methyl.

19 . The compound of claim 1 , wherein L 3 is a bond, R 3 is n-propylene, X 2 is S, R 4 and R 5 are each methyl.

20 . The compound of claim 1 , wherein L 3 is a bond, R 3 is ethylene, X 2 is S, and R 4 and R 5 are each ethyl.

21 . The compound of claim 1 , selected from the group consisting of the compounds of formula ATX-001 to ATX-028, and ATX-031

22 . A compound of formula I

wherein

R 1 and R 2 are the same or different, each a linear or branched alkyl consisting of 1 to 9 carbons, an alkenyl or alkynyl consisting of 2 to 11 carbons, or cholesteryl,

L 1 and L 2 are the same or different, each a linear alkylene or alkenylene consisting of 3 or 4 carbons,

X 1 is —CO—O— whereby -L 2 -CO—O—R 2 is formed,

X 2 is S or O,

X 3 is —CO—O— whereby -L 1 -CO—O—R 1 is formed,

L 3 is a bond,

R 3 is a linear or branched alkylene consisting of 1 to 6 carbons, and R 4 and R 5 are the same or different, each hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons;

or a pharmaceutically acceptable salt thereof.

23 . The compound of claim 22 consisting of the compound of formula ATX-029

24. A compound of formula 1:

wherein:

R 1 and R 2 are different and are each a linear or branched alkyl consisting of 1 to 9 carbons, an alkenyl consisting of 2 to 11 carbons, alkynyl consisting of 2 to 11 carbons, or cholesteryl,

L 1 and L 2 are the same or different, and are each a linear alkylene or alkenylene consisting of 5 to 18 carbons,

X 1 is —CO—O— whereby -L 2 -CO—O—R 2 is formed,

X 2 is S or O,

X 3 is —CO—O— whereby -L 1 -CO—O—R 1 is formed,

L 3 is a bond,

R 3 is a linear or branched alkylene consisting of 1 to 6 carbons, and

R 4 and R 5 are the same or different, and are each hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons;

or a pharmaceutically acceptable salt thereof.

25. The compound of claim 24 , wherein the alkenyl of R 1 and R 2 each consists of a single double bond.

26. A compound of formula 1:

wherein:

R 1 and R 2 are the same and are each a linear or branched alkyl consisting of 1 to 9 carbons, an alkynyl consisting of 2 to 11 carbons, or cholesteryl,

L 1 and L 2 are the same or different, each a linear alkylene or alkenylene consisting of 5 to 18 carbons,

X 1 is —CO—O— whereby -L 2 -CO—O—R 2 is formed,

X 2 is S or O,

X 3 is —CO—O— whereby -L 1 -CO—O—R 1 is formed,

L 3 is a bond,

R 3 is a linear or branched alkylene consisting of 1 to 6 carbons, and

R 4 and R 5 are the same or different, each hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons;

or a pharmaceutically acceptable salt thereof.

27. The compound of claim 26 , wherein the X 2 is S.

28. The compound of claim 26 , wherein the R 3 is ethylene.

29. The compound of claim 26 , wherein the R 3 is n-propylene or isobutylene.

30. The compound of claim 26 , wherein the R 4 and R 5 are separately methyl, ethyl, or isopropyl.

31. The compound of claim 26 , wherein L 1 and L 2 are the same.

32. The compound of claim 26 , wherein L 1 and L 2 differ.

33. The compound of claim 26 , wherein L 1 or L 2 consists of a linear alkylene having seven carbons.

34. The compound of claim 26 , wherein L 1 or L 2 consists of a linear alkylene having nine carbons.

35. The compound of claim 26 , wherein R 1 and R 2 each consists of an alkyl.

36. The compound of claim 26 , wherein R 1 and R 2 each consists of nine carbons.

37. The compound of claim 26 , wherein R 1 and R 2 each consists of eleven carbons.

38. The compound of claim 26 , wherein R 1 and R 2 each consists of seven carbons.

Continuity (4)
Continuation 16351301 · Mar 12, 2019
Reissue 14546105 · Nov 18, 2014
Provisional Application 61905724 · Nov 18, 2013
Reissue 14546105 · Nov 18, 2014
References Cited (50)
US 4511069A · Kalat · 1985 [cited by applicant]
US 4778810A · Wenig et al. · 1988 [cited by applicant]
US 5849902A · Arrow et al. · 1998 [cited by applicant]
US 9011903B2 · Niitsu et al. · 2015 [cited by applicant]
US 9365610B2 · Payne · 2016 [cited by examiner]
US 9567296B2 · Payne · 2017 [cited by examiner]
US 9580711B2 · Payne · 2017 [cited by examiner]
US 9670152B2 · Payne · 2017 [cited by examiner]
US 9834510B2 · Payne · 2017 [cited by examiner]
US 9850202B2 · Payne et al. · 2017 [cited by applicant]
US 9896413B2 · Payne · 2018 [cited by examiner]
US 9951002B2 · Payne et al. · 2018 [cited by applicant]
US 10383952B2 · Payne · 2019 [cited by examiner]
US 10526284B2 · Payne et al. · 2020 [cited by applicant]
US 10781169B2 · Payne · 2020 [cited by examiner]
US 10961188B2 · Payne et al. · 2021 [cited by applicant]
US 10961895B2 · Higashino et al. · 2021 [cited by applicant]
US 10980895B2 · Payne et al. · 2021 [cited by applicant]
US RE49233E · Payne · 2022 [cited by examiner]
US 20120027803A1 · Manoharan et al. · 2012 [cited by applicant]
US 20130022665A1 · Niitsu et al. · 2013 [cited by applicant]
US 20130129811A1 · Kuboyama et al. · 2013 [cited by applicant]
US 20130274504A1 · Colletti et al. · 2013 [cited by applicant]
US 20130280305A1 · Kuboyama et al. · 2013 [cited by applicant]
US 20130330401A1 · Payne et al. · 2013 [cited by applicant]
CA 2876148A1 · 2013 [cited by applicant]
CA 2837101C · 2020 [cited by applicant]
CN 105873902A · 2016 [cited by applicant]
EP 1502576A2 · 2005 [cited by applicant]
FR 1481016A · 1967 [cited by applicant]
JP 61089286 · 1986 [cited by applicant]
JP 61136584 · 1986 [cited by applicant]
JP 2016538343A · 2016 [cited by applicant]
WO WO9207065A1 · 1992 [cited by applicant]
WO WO199207065A1 · 1992 [cited by applicant]
WO WO9315187A1 · 1993 [cited by applicant]
WO WO199315187A1 · 1993 [cited by applicant]
WO WO2010061880A1 · 2010 [cited by applicant]
WO WO2011136368A1 · 2011 [cited by applicant]
WO WO2011153493A2 · 2011 [cited by applicant]
WO WO2012170952A2 · 2012 [cited by applicant]
WO WO2012170952A9 · 2012 [cited by applicant]
WO WO2013065825A1 · 2013 [cited by applicant]
WO WO2013086373A1 · 2013 [cited by applicant]
WO WO2013185116A1 · 2013 [cited by applicant]
WO WO2015074085A1 · 2015 [cited by applicant]
WO WO2016081029A1 · 2016 [cited by applicant]
Zaragoza Dorwald, Side Reactions in Organic Synthesis, 2005, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Preface. p. IX. [cited by examiner]
Reusch, Virtual Textbook in Organic Chemistry, Heterocyclic Compounds, 1999, p. 5, Recovered from https://www2.chemistry.msu.edu/faculty/reusch/virttxtjml/ heterocy.htm. [cited by examiner]
International Patent Application No. PCT/US2014/066242; Int'l Search Report and the Written Opinion; dated Feb. 10, 2015; 10 pages. [cited by applicant]